We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+11.15%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$457M
AUM Growth
+$26.6M
Cap. Flow
+$8.53M
Cap. Flow %
1.86%
Top 10 Hldgs %
38.17%
Holding
99
New
16
Increased
39
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$16.5M
2
RGEN icon
Repligen
RGEN
+$7.52M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$6.71M
4
NVRO
NEVRO CORP.
NVRO
+$5.59M
5
DXCM icon
DexCom
DXCM
+$4.89M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$11.2M
2
VCEL icon
Vericel Corp
VCEL
+$5.11M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$4.72M
4
ARWR icon
Arrowhead Research
ARWR
+$4.65M
5
CDMO
Avid Bioservices, Inc. Common Stock
CDMO
+$4.27M

Sector Composition

Rank Sector Weight
1 Healthcare 95.62%
2 Technology 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOSS icon
26
Gossamer Bio
GOSS
$88.9M
$6.39M 1.4%
786,870
+203,980
+35% +$1.77M
NVRO
27
DELISTED
NEVRO CORP.
NVRO
$5.93M 1.3%
+35,792
New +$5.59M
CTLT
28
DELISTED
CATALENT, INC.
CTLT
$5.92M 1.29%
54,739
-24,787
-31% -$2.66M
PTGX icon
29
Protagonist Therapeutics
PTGX
$9.6B
$5.83M 1.28%
+130,000
New +$4.29M
APEN
30
DELISTED
Apollo Endosurgery, Inc.
APEN
$5.6M 1.22%
691,214
+616,214
+822% +$4.23M
BCRX icon
31
BioCryst Pharmaceuticals
BCRX
$2.64B
$5.57M 1.22%
351,961
+107,281
+44% +$1.46M
IONS icon
32
Ionis Pharmaceuticals
IONS
$9.21B
$5.44M 1.19%
136,380
+30,583
+29% +$1.2M
INFU icon
33
InfuSystem Holdings
INFU
$248M
$5.23M 1.14%
251,567
-27,266
-10% -$551K
AXGN icon
34
Axogen
AXGN
$2.61B
$5.14M 1.12%
237,652
+26,053
+12% +$527K
IMUX icon
35
Immunic
IMUX
$211M
$5.08M 1.11%
41,409
+1,287
+3% +$178K
IDXX icon
36
Idexx Laboratories
IDXX
$46.2B
$4.84M 1.06%
7,667
+35
+0.5% +$19.3K
CDXS icon
37
Codexis
CDXS
$159M
$4.67M 1.02%
206,067
+106,067
+106% +$2.3M
SPNE
38
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$4.62M 1.01%
225,000
+34,253
+18% +$704K
MNKD icon
39
MannKind Corp
MNKD
$1.23B
$4.39M 0.96%
805,047
+405,047
+101% +$1.75M
MRVI icon
40
Maravai LifeSciences
MRVI
$866M
$3.76M 0.82%
90,000
-22,500
-20% -$872K
MDGL icon
41
Madrigal Pharmaceuticals
MDGL
$12.4B
$3.54M 0.78%
36,393
-3,328
-8% -$394K
BBIO icon
42
BridgeBio Pharma
BBIO
$16.4B
$3.53M 0.77%
57,978
-7,196
-11% -$411K
OM icon
43
Outset Medical
OM
$90.6M
$3.52M 0.77%
4,689
+356
+8% +$272K
KOD icon
44
Kodiak Sciences
KOD
$2.64B
$3.41M 0.75%
36,702
+3,654
+11% +$351K
HBIO icon
45
Harvard Bioscience
HBIO
$27.6M
$3.35M 0.73%
+40,237
New +$2.85M
SUPN icon
46
Supernus Pharmaceuticals
SUPN
$2.73B
$3.09M 0.68%
+100,415
New +$3.08M
NOTV
47
DELISTED
Inotiv
NOTV
$3.07M 0.67%
115,000
+40,000
+53% +$1M
STRO icon
48
Sutro Biopharma
STRO
$415M
$3.04M 0.66%
16,339
-3,931
-19% -$769K
HCAT icon
49
Health Catalyst
HCAT
$132M
$2.8M 0.61%
50,515
-14,759
-23% -$786K
ETNB
50
DELISTED
89bio
ETNB
$2.54M 0.56%
135,848
+33,685
+33% +$752K
1
2
3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Parkman Healthcare Partners held 99 positions worth $457M, up 6.2% from $431M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Parkman Healthcare Partners's Q2 2021 filing shows 16 new, 39 increased, 27 reduced and 17 closed positions. Its largest new stake was Intuitive Surgical: 58,839 shares worth $18M. The largest sale was Amgen, an estimated $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Technology.

  • Parkman Healthcare Partners's largest Q2 2021 buy was Intuitive Surgical: 58,839 shares worth $18M.
  • Parkman Healthcare Partners added most to DexCom in Q2 2021, an estimated $4.89M increase.
  • Parkman Healthcare Partners's biggest Q2 2021 reduction was Vericel Corp, cutting an estimated $5.11M.
  • Parkman Healthcare Partners fully exited Amgen in Q2 2021, selling an estimated $11.2M.
  • Parkman Healthcare Partners's ten largest holdings make up 38% of its $457M portfolio in Q2 2021.
  • Parkman Healthcare Partners opened 16 new positions and closed 17 in Q2 2021.
  • Parkman Healthcare Partners's portfolio value rose 6.2% quarter-over-quarter to $457M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2021, filed 13 Aug 2021.